MBTD1

Across TCGA pan-cancer cohorts, MBTD1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of MBTD1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MBTD1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MBTD1 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

BLCA, KIRC, and CHOL are the cancer types where MBTD1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MBTD1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	III,IV	+0.734	<.001	9	view →
KIRC	All	All	+0.308	<.001	6	view →
CHOL	All	All	+1.547	<.001	5	view →
KICH	Female	All	−1.181	<.001	5	view →
KIRP	All	IV	+0.947	.013	4	view →
STAD	All	All	+0.455	.014	4	view →
LUSC	All	All	+0.422	.001	4	view →
LIHC	All	All	+0.366	.001	4	view →
THCA	All	All	−0.301	.005	3	view →
LUAD	All	All	+0.282	.020	2	view →
READ	All	III,IV	+0.280	.022	2	view →
PRAD	All	All	+0.269	.022	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

MBTD1–BLCA

Open the BLCA breakdown →